Podcasts about Gastroenterology

Send us a textWant a clear, human guide to modern IBD care without the jargon? We're joined by Janette Villalon, a physician assistant at UC Irvine's IBD Center, who brings a front-line view of what truly helps patients: personalized therapy choices, honest safety talk, and practical plans that fit real life. She traces the evolution from a handful of anti-TNFs to a wider toolkit—anti-integrins, IL-12/23 and IL-23 inhibitors, JAK inhibitors, and S1P modulators—and explains how we match treatments to goals like fast relief, fewer side effects, and coverage of extraintestinal issues such as arthritis, uveitis, and psoriasis.We dig into how APPs power the day-to-day of IBD clinics, from education to monitoring and rapid access, and how the GHAPP Conference and national societies elevated advanced practice training. Janette breaks down when clinical trials make sense, why strict inclusion criteria matter, and how logistics can steer decisions when someone is very sick. She demystifies biosimilars, outlining FDA standards that support confident switches when insurance demands it, and shares how she helps patients balance infusions, injections, or pills against travel, work, and adherence.For those planning a family, Janette offers timely guidance: aim for clinical and endoscopic remission three to six months before conception, continue pregnancy-safe maintenance therapy, and discuss starting low-dose aspirin at 12 to 16 weeks to lower preeclampsia risk, coordinated with maternal-fetal medicine.Looking ahead, we explore precision medicine and AI—predictive markers, microbiome insights, and smarter monitoring that could reduce trial-and-error and catch flares early. The throughline is empowerment: ask questions, read, return for follow-ups, and shape your care around your life. We close with community resources from the Crohn's & Colitis Foundation and a shout-out to Camp Oasis for young patients.If this conversation helped you, subscribe, share it with a friend, and leave a quick review—what's the one topic you want us to go deeper on next?Links: Gastroenterology & Hepatology Advanced Practice Providers (GHAPP) organization Camp Oasis- Crohn's & Colitis Foundation USAIBD Medication Guide- Crohn's & Colitis Foundation USAPregnancy & IBD video- Crohn's & Colitis Foundation USALet's get social!!Follow us on Instagram!Follow us on Facebook!Follow us on Twitter!

We are kicking off Season 7 with a HUGE announcement -- we have TWO new podcast cohosts!Hosts Drs. Temara Hajjat, Jennifer Lee, Peter Lu, and Jason Silverman take a look back at Season 6 and introduce our new podcast hosts, Drs. Amber Hildreth and Jordan Whatley! We get to know them a little better and also talk about ways we focus on wellness despite the craziness of our work (and non-work) lives.And sorry for the subpar audio quality -- Peter was recording from a hotel bathroom...See you all at the NASPGHAN Annual Meeting in Chicago later this week! #NASPGHAN25Support the showThis episode may be eligible for CME credit! Once you have listened to the episode, click this link to claim your credit. Credit is available to NASPGHAN members (if you are not a member, you should probably sign up). And thank you to the NASPGHAN Professional Education Committee for their review!As always, the discussion, views, and recommendations in this podcast are the sole responsibility of the hosts and guests and are subject to change over time with advances in the field.Check out our merch website!Follow us on Bluesky, Twitter, Facebook and Instagram for all the latest news and upcoming episodes.Click here to support the show.

Un nouvel épisode du Pharmascope est disponible! Dans ce 89ème épisode, premier d'une série de deux concernant l'usage du fer, Nicolas, Sébastien et Isabelle animeront vos globules rouges en vous parlant de l'évaluation d'une carence en fer, des indications de traitement ainsi que des différences cliniques entre les différentes formulations de fer. Les objectifs pour cet épisode sont les suivants: Interpréter un résultat de ferritine Identifier les patients pouvant bénéficier d'un traitement de fer Comparer les avantages et inconvénients cliniques des différentes formulations de fer    Ressources pertinentes en lien avec l'épisode Lignes directrices Snook J et coll. British Society of Gastroenterology guidelines for the management of iron deficiency anaemia in adults. Gut. 2021;70:2030-51. British Columbia Ministry of Health. Iron Deficiency – Diagnosis and Management. BCGuidelines.ca. Avril 2019. Article de revue Pasricha S-R et coll. Iron deficiency. Lancet. 2021;397:233-48. Document de l'INESSS sur l'utilisation du bilan martial Boughrassa F, Framarin A. Usage judicieux de 14 analyses biomédicales. Institut national d'excellence en santé et en services sociaux. Avril 2014. Revues du traitement de la carence en fer sans anémie Miles LF et coll. Intravenous iron therapy for non anaemic, iron deficient adults. Cochrane Database Syst Rev. 2019;12:CD013084. Houston BL et coll. Efficacy of iron supplementation on fatigue and physical capacity in non-anaemic iron-deficient adults: a systematic review of randomised controlled trials. BMJ Open. 2018;8:e019240. McKennitt D, Allan GM. Iron Supplementation in Non-Anemic Women with Unexplainable Fatigue: Another Tired Theory? Tools for Practice 79. Août 2016. Revue de la comparaison de l'efficacité et l'innocuité de types de fer Moe S, Allan GM. New iron supplements for anemia. Can Fam Phys. 2019;65(8):556. Étude portant sur la prise concomitante de vitamine C Li N et coll. The Efficacy and Safety of Vitamin C for Iron Supplementation in Adult Patients With Iron Deficiency Anemia: A Randomized Clinical Trial. JAMA Network Open. 2020;3:e2023644.

Un nouvel épisode du Pharmascope est disponible! Dans ce 90ème épisode et la deuxième et dernière partie de notre série concernant l'usage du fer, Nicolas, Sébastien et Isabelle décortiquent les subtilités de la posologie optimale de fer.  Les objectifs pour cet épisode sont les suivants: Comparer les avantages et les inconvénients des différentes posologies de fer possibles (prise intermittente, uniquotidienne, biquotidienne) Conseiller un patient lors de l'initiation d'un traitement de fer Expliquer dans quel contexte l'administration de fer intraveineux est indiqué   Ressources pertinentes en lien avec l'épisode Lignes directrices Snook J et coll. British Society of Gastroenterology guidelines for the management of iron deficiency anaemia in adults. Gut. 2021;70:2030-51. British Columbia Ministry of Health. Iron Deficiency – Diagnosis and Management. BCGuidelines.ca. Avril 2019. Article de revue Pasricha S-R et coll. Iron deficiency. Lancet. 2021;397:233-48. Articles portant sur la posologie du fer oral Lee H et coll. Iron dosing frequency. Can Fam Physician. 2021;67:436. Rimon E et coll. Are we giving too much iron? Low-dose iron therapy is effective in octogenarians. Am J Med. 2005;118:1142-7. Fernandez-Gaxiola AC, De-Regil LM. Intermittent iron supplementation for reducing anaemia and its associated impairments in adolescent and adult menstruating women. Cochrane Database Syst Rev. 2019;1:CD009218. Düzen Oflas N et coll. Comparison of the effects of oral iron treatment every day and every other day in female patients with iron deficiency anaemia. Intern Med J. 2020;50:854-8. Kaundal R et coll. Randomized controlled trial of twice-daily versus alternate-day oral iron therapy in the treatment of iron-deficiency anemia. Ann Hematol. 2020;99:57-63. Utilisation du fer intraveineux Litton E et coll. Safety and efficacy of intravenous iron therapy in reducing requirement for allogeneic blood transfusion: systematic review and meta-analysis of randomised clinical trials. BMJ. 2013;347:f4822. Ponikowski P et coll. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. Lancet. 2020;396:1895-1904.

Dr. Lisa Mathew interviews Mallika Khandelwal, founder and CEO of Squad Health, and Tasha Cieslak, practice manager of Louisiana Gastroenterology Associates about how independent GI practices can streamline the management of complex prescription workflows. Squad Health is an AI-enabled healthcare technology company developing solutions to streamline access to specialty medications and reduce the workload around prior authorizations and appeals. Join Lisa, Mallika, and Tasha as they discuss how technology can ease administrative burden in gastroenterology, what early automation looks like inside a busy practice, and the innovations ahead for practices adopting AI-driven solutions to improve efficiency and access to care. Produced by Andrew Sousa and Hayden Margolis for Steadfast Collaborative, LLC Mixed and mastered by Hayden Margolis Gastro Broadcast, Episode 84, presented by TissueCypher from Castle Biosciences

Co-hosts Ryan Piansky, a graduate student and patient advocate living with eosinophilic esophagitis (EoE) and eosinophilic asthma, and Holly Knotowicz, a speech-language pathologist living with EoE who serves on APFED's Health Sciences Advisory Council, interview Dr. Andrew Lee, Vice President, Clinical Research at Uniquity Bio, about Thymic Stromal Lymphopoietin (TSLP) and eosinophilic esophagitis (EOE). Disclaimer: The information provided in this podcast is designed to support, not replace, the relationship between listeners and their healthcare providers. Opinions, information, and recommendations shared in this podcast are not a substitute for medical advice. Decisions related to medical care should be made with your healthcare provider. Opinions and views of guests and co-hosts are their own.   Key Takeaways: [:49] Co-host Ryan Piansky introduces the episode, brought to you thanks to the support of Education Partners Bristol Myers Squibb, GSK, Sanofi, Regeneron, and Takeda. Ryan introduces co-host Holly Knotowicz.   [1:13] Holly introduces today's topic, Thymic Stromal Lymphopoietin (TSLP) and eosinophilic esophagitis (EOE), and today's guest, Dr. Andrew Lee, Vice President, Clinical Research at Uniquity Bio.   [1:36] Dr. Lee has nearly 20 years of experience in the clinical development of new vaccines, biologics, and drugs. Holly welcomes Dr. Lee.   [1:52] Dr. Lee trained in internal medicine and infectious diseases.   [1:58] Dr. Lee has been fascinated by the immune system and how it can protect people against infections, what happens when immunity is damaged, as in HIV and AIDS, and how to apply that knowledge to boost immunity with vaccines to prevent infections.   [2:16] Dr. Lee led the clinical development for a pediatric combination vaccine for infants and toddlers. It is approved in the U.S. and the EU.   [2:29] Dr. Lee led the Phase 3 Program for a monoclonal antibody to prevent RSV, a serious infection in infants. That antibody was approved in June 2025 for use in the U.S.   [2:44] In his current company, Dr. Lee leads research into approaches to counteract an overactive immune system. They're looking at anti-inflammatory approaches to diseases like asthma, EoE, and COPD.   [2:58] Dr. Lee directs the ongoing Phase 2 studies that they are running in those areas.   [3:28] Dr. Lee sees drug development as a chance to apply cutting-edge research to benefit people. He trained at Bellevue Hospital in New York City in the 1990s.   [3:40] When Dr. Lee started as an intern, there were dedicated ICU wards for AIDS patients because many of the sickest patients were dying of AIDS and its complications.    [3:52] Before the end of Dr. Lee's residency, they shut down those wards because the patients were on anti-retroviral medications and were doing so well that they were treated as outpatients. They didn't need dedicated ICUs for AIDS patients anymore.   [4:09] For Dr. Lee, that was a powerful example of how pharmaceutical research and drug regimen can impact patients' lives for the better by following the science. That's what drove Dr. Lee to go in the direction of research.   [4:48] Dr. Lee explains Thymic Stromal Lymphopoietin (TSLP). TSLP serves as an alarm signal for Type 2 or TH2 inflammation, a branch of the immune responses responsible for allergic responses and also immunity against parasites.   [5:17] When the cells that line the GI tract and the cells that line the airways in our lungs receive an insult or an injury, they get a danger signal, then they make TSLP.   [5:28] This signal activates other immune cells, like eosinophils and dendritic cells, which make other inflammatory signals or cytokines like IL-4, IL-13, and IL-5.   [5:47] That cascade leads to inflammation, which is designed to protect the body in response to the danger signal, but in some diseases, when there's continued exposure to allergens or irritants, that inflammation goes from being protective to being harmful.   [6:15] That continued inflammation, over the years, can lead to things like the thickened esophagus with EoE, or lungs that are less pliant and less able to expand, in respiratory diseases.   [6:48] Dr. Lee says he thinks of TSLP as being a master switch for this branch of immune responses. If you turn on TSLP, that turns on a lot of steps that lead to generating an allergic type of response.   [7:06] It's also the same type of immune response that can fight off parasite infections. It's the first step in a cascade of other steps generating that type of immune response.   [7:30] Dr. Lee says people have natural genetic variation in the genes that incur TSLP.   [7:38] Observational studies have found that some people with genetic variations that lead to higher levels of TSLP in their bodies had an increased risk for allergic inflammatory diseases like EoE, atopic dermatitis, and asthma.   [8:13] Studies like the one just mentioned point to TSLP being important for increased risk of developing atopic types of diseases like EoE and others. There's been some work done in the laboratory that shows that TSLP is important for activating eosinophils.    [8:38] There's accumulating evidence that TSLP activation leads to eosinophil activation, other immune cells, or white blood cells getting activated.   [9:07] Like a cascade, those cells turn on T-cells and B-cells, which are like vector cells. They lead to direct responses to fight off infections, in case that's the signal that leads to the turning on TSLP.   [9:48] Ryan refers to a paper published in the American Journal of Gastroenterology exploring the role of TSLP in an experimental mouse model of eosinophilic esophagitis. Ryan asks what the researchers were aiming to find.   [10:00] Dr. Lee says the researchers were looking at the genetic studies we talked about, the observational studies that are beginning to link more TSLP with more risk for EoE and those types of diseases.   [10:12] The other type of evidence that's accumulating is from in vitro (in glass) experiments or test tube experiments, where you take a couple of cells that you think are relevant to what's going on.   [10:28] For example, you could get some esophageal cells and a couple of immune cells, and put TSLP into the mix, and you see that TSLP leads to activation of those immune cells and that leads to some effects on the esophageal cells.   [10:42] Those are nice studies, but they're very simplified compared to what you can do in the body. These researchers were interested in extending those initial observations from other studies, but working in the more realistic situation of a mouse model.   [11:00] You have the whole body of the mouse being involved. You can explore what TSLP is doing and model a disease that closely mimics what's happening with EoE in humans.   [12:23] They recreated the situation of what seems to be happening in EoE in people. We haven't identified it specifically, but there's some sort of food allergen in patients with EoE that the immune system is set off by.   [12:55] What researchers are observing in this paper is that in these mice that were treated with oxazolone, there is inflammation in the esophagus, an increase in TSLP levels, and eosinophils going into the esophageal tissues.   [13:15] Dr. Lee says, that's one of the main ways we diagnose EoE; we take a biopsy of the esophagus and count how many eosinophils there are. Researchers saw similar findings. The eosinophil count in the esophageal tissues went way up in these mice.    [13:34] Researchers also saw other findings in these mice that are very similar to EoE in humans, such as the esophageal cells lining the esophagus proliferating. They even saw that new blood vessels were being created in that tissue that's getting inflamed.   [14:00] Dr. Lee thinks it's a very nice paper because it shows that correlation: Increase TSLP and you see these eosinophils going to the esophagus, and these changes that are very reminiscent of what we see in people with EoE.   [14:51] In this paper, the mice made the TSLP, and researchers were able to measure the TSLP in the esophageal tissue. The researchers didn't introduce TSLP into the mice. The mice made the TSLP in response to being repeatedly exposed to oxazolone.   [15:20] That's key to the importance of the laboratory work. The fact that the TSLP is made by the mice is important. It makes it a very realistic model for what we're seeing in people.   [15:41] In science, we like to see correlation. The researchers showed a nice correlation.   [15:46] When TSLP went up in these mice, and the mice were making more TSLP on their own, at the same time, they saw all these changes in the esophagus that look a lot like what EoE looks like in people.    [16:01] They saw the eosinophils coming into the esophagus. They saw the inflammation go up in the esophagus. What Dr. Lee liked about this paper is that they continued the story.   [16:15] The researchers took something that decreases TSLP levels, an antibody that binds to and blocks TSLP, and when they did that, they saw the TSLP levels come down to half the peak level.   [16:35] Then they saw improvement in the inflammation in the esophagus. They saw that the amount of eosinophils decreased, and the multiplication of the esophageal cells went down. The number of new blood vessels went down after the TSLP was reduced.   [16:53] Dr. Lee says, you see correlation. The second part is evidence for causation. When you take TSLP away, things get better. That gives us a lot of confidence that this is a real finding. It's not just observational. There is causation evidence here.   [18:26] Ryan asks if cutting TSLP also help reduce other immune response cells. Dr. Lee says TSLP is the master regulator for this Type 2 inflammation. It definitely touches and influences other cells besides eosinophils.   [18:44] TSLP affects dendritic cells, which are an important type of immune cell, like a coordinating cell that instructs other cells within the immune system what to do. In this paper, they looked at a lot of other effects of TSLP on the tissues of the body.   [19:10] Dr. Lee says, There's a lot of research on TSLP, and one of the reasons we're excited about the promise of TSLP is that it's so far upstream; so much of the beginning, that it's affecting other cells.   [19:29] Its effects could be quite broad. If we're able to successfully block TSLP, we could block a lot of different effects.   [19:40] One treatment for EoE is dupilumab, which blocks IL-4 and IL-13 specifically, and that works well, but TSLP has the potential to have an even greater effect than blocking IL-4 and IL-13, since it is one step before turning on IL-4 and IL-13.    [20:14] That's one of the reasons researchers are excited about the promise of blocking TSLP. There are studies ongoing of TSLP blockers in people with EoE.   [20:34] Ryan asks if there are negative repercussions from blocking TSLP. Dr. Lee says in this study and in people, we are not completely blocking TSLP by any means. There will still be residual TSLP activated, even with very potent drugs.   [21:01] In the study, they block TSLP about 50%‒60%. TSLP is involved in immunity against parasites. In studies with people, they make sure not to include anybody who has an active parasitic infection. A person under treatment should not be in a study.   [21:27] Dr. Lee says we haven't seen any problems with parasitic infections becoming more severe, but that is a theoretical possibility, so for that reason, in studies with TSLP blockers, we generally exclude patients with known parasitic infections.   [22:17] What excited Dr. Lee in this paper was that they showed that when you block TSLP in the mice, then you get real effects in their tissues. Eosinophils went away. The thickening of the basal layers in the esophagus got much better.   [22:38] That kind of real effect reflected in the tissue is super exciting to see. That gives us more confidence that this could work in people, since we're seeing it in a realistic whole-body model in the mice.   [23:12] Dr. Lee says there are ongoing clinical studies on TSLP blockers for EoE. His company is studying an antibody that blocks TSLP in eczema, COPD, and EoE. One of the exciting things about immunology is that it affects many different parts of the body.   [23:42] EoE is associated with other immune-type disorders. There's a high percentage of patients with EoE who have other diseases. EoE coexists with asthma, atopic dermatitis, and chronic rhinitis.   [24:09] It's exciting that if you figure out something that's promising for one disease that TSLP affects, it could have very broad-ranging implications for a variety of diseases.   [24:22] Ryan shares his experience of his doctor talking to him about a TSLP blocker, tezepelumab, as a potential option when it's out of clinical trials. It would target something a little higher up the chain and help with some of his remaining symptoms.   [24:59] Ryan is excited to hear that this research is so encouraging and how it could potentially help treat EoE, asthma, and other conditions, all at once.   [25:16] Dr. Lee says that being in these later-stage studies is super exciting. If these late-stage trials are successful, the next step is to apply for regulatory approval with the various agencies around the world.   [26:40] Dr. Lee shares one takeaway for listeners to remember. Think of TSLP as an alarm that turns on inflammation. He compares TSLP to turning on an alarm during a robbery. There are multiple steps designed to protect the bank and the money.   [27:20] To extend that analogy, with TSLP, once you turn it on, all these other steps are going to happen. Inflammation is designed to protect the body. It's a protective response. If there's an infection, it can clear the infection.   [27:38] If the infection persists, as in HIV, the immune response, which is protective and beneficial, eventually becomes damaging. It becomes dysfunctional. In EoE, if you continually eat the allergic food, the inflammation becomes damaging to the esophagus.   [28:27] Long-term inflammation leads to replacing the normal esophageal tissue with fibrotic tissue, and that's why the esophagus eventually gets hardened and less able to let the food go through.   [28:40] In respiratory diseases, the soft tissue of the lung gets replaced with thicker tissue, and the lung is not able to expand.   [28:54] Dr. Lee says he people to think about TSLP as this master alarm switch. We hope that if you could turn off that TSLP, you could then avoid a lot of the complications that we see with chronic inflammation in these conditions.   [29:14] We're hopeful that you could even take away the symptoms that you see in these diseases, make patients feel better, and with extended treatment, you could begin to reverse some of the damage resulting from inflammation.   [29:32] Ryan likes that analogy and how Dr. Lee has concisely explained these complicated concepts.   [29:51] Dr. Lee thanks Holly and Ryan and adds one more plea to listeners. Please consider getting involved with research. Clinical trials cannot be done without patients. We need patients to advance new treatments.   [30:27] Researchers like Dr. Lee spend a lot of time thinking about how to make the studies not only informative but also fair to patients who decide to become involved. It's a lot of work and a fair amount of time commitment.   [30:44] If you don't want to be in a study, you can help by being on a patient feedback panel and reviewing protocols and informed consents. Follow your interests. Think about getting involved with research, however you can.   [31:06] Ryan and Holly are very grateful for the community, with so many wonderful clinicians and researchers, and so many patients who are willing to volunteer their time and their data to help researchers find better solutions going forward.   [31:26] Ryan thanks Dr. Lee for coming on and putting out that call to action. It's a great reminder for listeners and the patients in the community to look for those opportunities. Chat with your physician. Go to APFED's website. There's a link to active clinical trials.   [31:47] For our listeners who want to learn more about eosinophilic disorders, we encourage you to visit apfed.org and check out the links in the show notes below.   [31:53] For those looking to find specialists who treat eosinophilic disorders, we encourage you to use APFED's Specialist Finder at apfed.org/specialist.   [32:01] If you'd like to connect with others impacted by eosinophilic diseases, please join APFED's online community on the Inspire Network at apfed.org/connections.   [32:11] Ryan thanks Dr. Andrew Lee for joining us today. We learned a lot. Holly also thanks APFED's Education Partners Bristol Myers Squibb, GSK, Sanofi, Regeneron, and Takeda for supporting this episode.   Mentioned in This Episode: Andrew Lee, M.D., VP Clinical Research, Uniquity Bio   "A Mouse Model for Eosinophilic Esophagitis (EoE)" Current Protocols, Wiley Online Library   APFED on YouTube, Twitter, Facebook, Pinterest, Instagram Real Talk: Eosinophilic Diseases Podcast apfed.org/specialist apfed.org/connections apfed.org/research/clinical-trials   Education Partners: This episode of APFED's podcast is brought to you thanks to the support of Bristol Myers Squibb, GSK, Sanofi, Regeneron, and Takeda.   Tweetables:   "I see drug development as a chance to apply cutting-edge research to benefit people." — Andrew Lee, M.D.   "When the cells that line the GI tract and the cells that line the airways in our lungs receive an insult or an injury, they get a danger signal, then they make TSLP." — Andrew Lee, M.D.   "Observational studies have found that some people with genetic variations that lead to higher levels of TSLP in their bodies had an increased risk for allergic inflammatory diseases like EoE, atopic dermatitis, and asthma." — Andrew Lee, M.D.   "There's a lot of research on TSLP, and one of the reasons we're excited about the promise of TSLP is that it's so far upstream; so much of the beginning, that it's affecting other cells." — Andrew Lee, M.D.   "Please consider getting involved with research. We can't do these clinical trials without patients. We need patients to advance new treatments for patients." — Andrew Lee, M.D.

Dr. Hoffman continues his conversation with Dr. Alexandra Shustina, NYC's and Miami's premier Integrative board-certified Gastroenterologist and gut health specialist, an expert in the gut microbiome and its role in health and wellness.

In this episode of the Intelligent Medicine podcast, Dr. Ronald Hoffman is joined by Dr. Alexandra Shustina, a distinguished integrative gastroenterologist based in New York City and Miami. They delve into Dr. Shustina's journey from conventional to integrative medicine, the importance of addressing the microbiome, and holistic approaches to treating gastrointestinal ailments like IBS, Crohn's disease, and ulcerative colitis. Dr. Shustina shares her insights on diet, the impact of stress, and the role of supplements and herbal remedies. She discusses the significance of personalized care, visceral manipulation, and mind-body techniques in promoting gut health. The episode also touches on the rising incidence of gastrointestinal cancers in young people and the potential benefits of proactive, integrative healthcare approaches.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Paul Adams, MD Hemochromatosis, a genetic condition that causes the body to absorb too much iron from food, often goes unrecognized despite its prevalance. With unique diagnostic and management challenges, it's crucial to understand how it presents, which testing strategies are most effective, and what treatment options are available. Tune in to hear Dr. Peter Buch and Dr. Paul Adams, Professor in the Division of Gastroenterology at the Western University in London, Canada, discuss the latest on hemochromatosis.

Send us a textDr. Acosta returns to Causes or Cures to talk about the next big leap in obesity research: using genetics and machine learning to predict which patients will get side effects to popular GLP-1 weight-loss medications like Wegovy and Zepbound. Previously, he was on Causes or Cures to discuss your individual obesity type. He and his team are uncovering why some people experience major weight loss while others face tough side effects—especially nausea. The goal? True precision medicine for obesity: matching the right treatment to the right person before treatment even begins. (You can learn more about their available tests and company here.) Topics We DiscussDr. Acosta's background and what drew him to obesity researchWhy not all obesity is the same—and why that matters for patients and doctorsThe most common questions patients ask about GLP-1 drugs like Wegovy and ZepboundHow big a problem side effects like nausea really are in practiceNew research using genetic markers to predict who's more likely to experience side effectsWhether eating style affects nausea and how Dr. Acosta coaches patients on nutrition while using these medicationsThe possibility of genetic testing before prescribing GLP-1sWhat we know about rarer side effects, from vision to hearing changes, if he thinks more side effects will emergeWhat “satiation” (feeling full) means and why it varies so much between peopleHow genetic risk and satiation scores could determine which obesity treatment works bestDr. Acosta's thoughts on obesity prevention, especially on renewed energy to take on the unhealthy food industryThe persistence of stigma—why “willpower” doesn't tell the whole storyWhether the current obsession with obesity drugs distracts from prevention, nutrition, and community health Listen if you've ever wondered:Why GLP-1 drugs don't work the same for everyoneWhat your genes have to do with weight loss, feeling full and side effectsHow soon doctors could use genetic tests to personalize obesity treatmentWhether prevention is being overshadowed by the pharma spotlightWhy it mattersObesity isn't a one-size-fits-all condition—and neither should its treatment be. Dr. Acosta's research could mark a turning point in how we approach weight loss: scientifically, compassionately, and individually. Dr. Acosta is a Consultant of Gastroenterology and Hepatology at the Mayo Clinic, as well as an Associate Professor of Medicine. His research focus is on gastrointestinal physiology and the complexity of food intake regulation as it relates to obesity. You can learn more about his work here.You can contact Dr. Eeks at bloomingwellness.com.Follow Eeks on Instagram here.Or Facebook here.Or X.On Youtube.Or TikTok.SUBSCRIBE to her WEEKLY newsletter here! (Now featuring interviews with top experts on health you care about!)Support the show

Send us a textA boxer in training. A terrifying spiral of symptoms. A life-saving surgery that changed everything. Jose Torres joins us to share how ulcerative colitis pulled him out of the ring and propelled him into purpose—building community, advancing equity, and living well with a J‑pouch in a city that isn't designed for urgent needs.We trace Jose's path from misdiagnosis in Brooklyn to specialized care in Manhattan and the brutal logistics of public transit without bathrooms. He opens up about the cultural currents in his Mexican and Puerto Rican family—why speaking up took time, why steroids raised tough questions, and how food traditions collided with new IBD realities. The story turns on resilience: a colectomy and J‑pouch, early pouchitis, iron infusions, and then a decade of medication-free stability supported by smart nutrition, consistent exercise, and honest attention to mental health.Jose also brings us inside the Crohn's & Colitis Foundation—from literally ringing the office doorbell to roles in advancement, business development, and DEI leadership. We talk about real lived experience, research into disparities, and why culturally fluent care changes outcomes. Along the way, he shares practical tactics for managing frequency, a nudge toward pelvic floor physical therapy, and a grounded philosophy: don't chase perfection, cultivate accountability and hope.If stories of grit, culture, and community help you feel less alone with IBD, this one's for you. Cheers!Links: Camp Oasis- Crohn's & Colitis Foundation USACamp Purple- Crohn's & Colitis Foundation New ZealandAbout IBD podcast with Amber Tresca episode- "IBD in the Hispanic Community with Dr. Oriana Damas"Let's get social!!Follow us on Instagram!Follow us on Facebook!Follow us on Twitter!

In this episode of Bowel Sounds, hosts Dr. Peter Lu and Dr. Jenn Lee talk to Dr. Kevin Watson, pediatric gastroenterologist and Assistant Director of Clinical Informatics at Akron Children's Hospital and Associate Professor at Northeastern Ohio Medical University. We talk about the use of AI-powered ambient listening technology for clinical documentation and his experience introducing AI scribes to his hospital.Learning objectivesUnderstand the advantages and limitations of the current state of ambient listening technology for clinical documentation.Review practical guidance on usage of this technology in pediatric gastroenterology.Recognize key strategies for successful implementation and adoption of this technology.Support the showThis episode may be eligible for CME credit! Once you have listened to the episode, click this link to claim your credit. Credit is available to NASPGHAN members (if you are not a member, you should probably sign up). And thank you to the NASPGHAN Professional Education Committee for their review!As always, the discussion, views, and recommendations in this podcast are the sole responsibility of the hosts and guests and are subject to change over time with advances in the field.Check out our merch website!Follow us on Bluesky, Twitter, Facebook and Instagram for all the latest news and upcoming episodes.Click here to support the show.

Money is a tool. Freedom is the goal. A plan is the bridge. Join us for a powerful conversation with Dr. Latifat Akintade, a board-certified gastroenterologist, founder of MoneyFitMD and The Money Coaching School for Women Physicians, bestselling author of The Power to Choose and Done With Broke, and host of the MoneyFitMD Podcast.We will cover the mindset and mechanics that help women physicians achieve true financial freedom without losing wellness or identity. Learn how to create a simple money plan, pay off six-figure debt, grow your net worth, and invest with confidence. Discover how to align money choices with your values, career, and life.About Dr. LatifatDr. Latifat Akintade trained at the University of California, Davis School of Medicine, completed Internal Medicine residency at the Icahn School of Medicine at Mount Sinai and Mount Sinai Hospital, and pursued Gastroenterology fellowship at the University of California, San Francisco School of Medicine. She is board certified in Gastroenterology by the American Board of Internal Medicine. As the visionary behind MoneyFitMD and The Money Coaching School for Women Physicians, she blends clinical expertise, money coaching, and life coaching to help women physicians build wealth without sacrificing wellness or identity. She is a sought after speaker, an Amazon bestselling author, a dynamic podcast host, and a proud mother of three daughters who loves great books, loud laughs, and ocean views.What you will learnA step by step money plan for women physiciansHow to crush debt and build wealth with clarityInvesting basics that reduce stress and boost confidenceHow to protect wellness while you grow your net worthThe power of choice in career, family, and freedomLearn more.www.moneyfitmd.com

Tune in to listen as expert faculty, Dr Christopher L. Bowlus and Dr Sonal Kumar, discuss recent developments in treating primary biliary cholangitis (PBC) with new and emerging agents, as well as strategies to integrate these advances into clinical practice.Topics covered include: Methods of Assessing PBC Disease ProgressionNewer Agents for Second-line Treatment of PBCPrioritizing Symptom Management and Quality of Life With PBC TreatmentPresenters:Christopher L. Bowlus, MDLena Valenta Professor and ChiefDivision of Gastroenterology and HepatologySchool of Medicine University of California Davis Sacramento, CaliforniaSonal Kumar, MD, MPHAssistant Professor of MedicineDivision of Gastroenterology and HepatologyWeill Cornell Medical CollegeNew York, New YorkLink to full program: https://bit.ly/43nHx6UGet access to all of our new podcasts by subscribing to the CCO Medical Specialties Podcast on Apple Podcasts, Google Podcasts, or Spotify.     Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Dr. Parameshwara C M is a distinguished general and colorectal surgeon with over 25 years of dedicated experience, known for his pioneering contributions to the field of proctology. He is the founder of SMILES Institute of Gastroenterology, India's leading single-speciality gastroenterology hospital, renowned for its advanced treatments and exceptional medical outcomes.With a record of 40,000+ surgeries, Dr. Parameshwara has performed the highest number of fistula surgeries in the world over the past six years. His innovative techniques and unmatched precision have earned him the nickname “Picasso of Fistula Surgery.” He has been at the forefront of introducing minimally invasive procedures such as LIFT, VAAFT, and STARR in India, transforming patient care and recovery.Internationally trained in the U.S., Germany, and Singapore, Dr. Parameshwara combines global expertise with deep-rooted clinical excellence. His commitment to innovation, quality care, and surgical mastery has garnered numerous accolades, including the Achievers of Karnataka Award, and positioned him as a benchmark-setter in colorectal and gastrointestinal surgery.Address: 1st Main, 1st Stage, 423, 60 Feet Rd, near SBI Bank, Gokula 1st Stage, Gokula Extension, Mathikere, Bengaluru, Karnataka 560054https://maps.app.goo.gl/XCjTg2jN1dSPu...Phone: 8010540540

Pediatrician Dr. Paul Bunch consults Dr. Kahleb Graham from the Division of Gastroenterology, Hepatology, and Nutrition and Dr. Megan Miller from the Division of Behavioral Medicine and Clinical Psychology on disorders of gut-brain interaction. Episode recorded on September 17, 2025.    Resources discussed in this episode: Anxiety Assessment - Community Practice Support Tool Anxiety Management - Community Practice Support Tool Chronic Nausea and Vomiting - Community Practice Support Tool  Functional Abdominal Pain - Community Practice Support Tool     Financial Disclosure:  The following relevant financial relationships have been disclosed: None All relevant financial relationships listed have been mitigated. Remaining persons in control of content have no relevant financial relationships. To Claim Credit: Click "Launch Activity." Click "Launch Website" to access and listen to the podcast. After listening to the entire podcast, click "Post Test" and complete.   Accreditation In support of improving patient care, Cincinnati Children's Hospital Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Specific accreditation information will be provided for each activity. Physician:  Cincinnati Children's designates this Enduring Material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.  Nursing:  This activity is approved for a maximum 0.75 continuing nursing education (CNE) contact hours. ABP MOCpt2: Completion of this CME activity, which includes learner assessment and feedback, enables the learner to earn up to 0.75 points in the American Board of Pediatrics' (ABP) Maintenance of Certification (MOC) program. Cincinnati Children's submits MOC/CC credit for board diplomates.   Credits AMA PRA Category 1 Credits™ (0.75 hours), ABP MOC Part 2 (0.75 hours), CME - Non-Physician (Attendance) (0.75 hours), Nursing CE (0.75 hours)  

Episode 38 - Countdown to Chicago: What's Ahead at the CPNP Nutrition SymposiumIn this episode of Nutrition Pearls: the Podcast, host Nikki Misner speaks with Dr. Brock Williams and Tamara Sims Dorway about the upcoming CPNP Nutrition Symposium at the annual NASPGHAN meeting on November 6-8th in Chicago, Illinois. Brock Williams is a Registered Dietitian and Postdoctoral Research Fellow at the University of British Columbia (Vancouver, Canada). Over the past 10 years, he has worked as both a clinical and research dietitian at the Hospital for Sick Children (SickKids; Toronto), and at BC Children's Hospital (Vancouver) in areas such as Translational Medicine, Gastroenterology, and Allergy. His major clinical and research interests lie in micronutrients and childhood feeding (human milk feeding, complementary feeding and the prevention and treatment of food allergy). Brock currently serves as President-elect of CPNP. Tamara Sims Dorway is an experienced Registered Dietitian who is a board-certified specialist in pediatric nutrition. She is an integral part of the multidisciplinary team at the Center for Digestive Health and Nutrition at Arnold Palmer Hospital, where she provides comprehensive nutritional care for children and families facing a range of GI challenges. She has previously served on the CPNP planning committee for NASPGHAN and was the communications co-chair for POWER (Pediatric Obesity Weight Evaluation Registry).  She enjoys volunteering in her community and spending time with her family. She is the current CPNP Program ChairNutrition Pearls is supported by an educational grant from Mead Johnson Nutrition.Resources:NASPGHAN 2025 Annual Meeting NASPGHAN 2025 App Produced by: Corey IrwinNASPGHAN - Council for Pediatric Nutrition Professionalscpnp@naspghan.org

Send us a textImagine being able to turn down the volume on gut pain, food fear, and medical anxiety—without white-knuckle coping or guesswork. We sit down with Dr. Ali Navidi, co-founder of GIpsychology.com and past president of the Northern Virginia Society of Clinical Hypnosis, to unpack how clinical hypnosis and gut-focused CBT help people with inflammatory bowel disease interrupt the gut-brain loop that keeps symptoms alive. No stage tricks here—just practical tools that retrain the nervous system, reduce visceral hypersensitivity, and restore a sense of control.We explore the real differences between stage and clinical hypnosis and why trance is a natural state you already know how to access. Dr. Navidi explains how anchors—a simple conditioned cue—can trigger a calming response within seconds, whether you're prepping for a colonoscopy, calling the insurance company, or navigating an unexpected flare. We dig into disorders of gut-brain interaction (DGBIs) that can drive symptoms even when labs look great, and why gut-focused CBT plus hypnosis outperforms one-size-fits-all mental health approaches for persistent GI distress.Trauma and nocebo effects show up in subtle ways across the IBD journey. We get candid about medical trauma, memory reconsolidation, EMDR as a hypnotic protocol, and how conditioned food sensitivities form—like the “pizza panic” that lingers long after a flare. You'll hear how to calm hypervigilance, rebuild trust with your body, and reintroduce foods safely. We also share details on a new eight-week telehealth group, created with the Crohn's & Colitis Foundation and the American College of Gastroenterology, that pairs weekly skills training with recorded hypnosis sessions for daily practice.Ready to try tools that actually change how your system reacts? Follow, share with a friend who needs hope, and leave a review to help others find the show. Your story might be the anchor someone else needs today.Links: Information about the IBD Psychotherapy GroupInformation on Disorder of the Gut-Brain Interaction (DGBI)Great resources from GI PsychologyArticle in the AtlanticDr. Navidi on the About IBD Podcast with Amber TrescaLet's get social!!Follow us on Instagram!Follow us on Facebook!Follow us on Twitter!

Gastroenterology offers a unique and dynamic landscape for innovation and entrepreneurship but as providers we are often not aware of what steps we need to take. In today's episode, Dr. Parikh interviews Dr. Amitabh Chak, president of the American Society of Gastrointestinal Endoscopy. Dr. Chak shares his latest innovation trends in GI, key steps every GI entrepreneur should take, barriers we face, and how ASGE is creating the infrastructure to support this ecosystem. With this infrastructure in mind, they highlight ASGE's upcoming Festival of Innovation and EndoScopic Technology at ASGE (FIESTA) on November 14th and 15th. For those interested in learning more or registering for FIESTA, please visit www.ASGE.org/FIESTA. 

In this episode, hosts Drs. Temara Hajjat and Jenn Lee talk to Dr. Jordan Whatley, Assitant Professor of Pediatrics at the Medical University of South Carolina and pediatric gastroenterologist at Shawn Jenkins Children's Hospital in Charleston, South Carolina. We discuss how multi-specialty clinics focusing on children with tracheostomy and ventilator dependence can improve clinical care.Learning Objectives:Describe the reasons children may require a tracheostomy and home mechanical ventilation.Explain multidisciplinary structure and purpose of an aerodigestive clinic in managing complex pediatric patients. Describe the gastroenterologist's role in evaluating and managing GERD, feeding intolerance, and nutritional needs in children with trach/vent dependence. Support the showThis episode may be eligible for CME credit! Once you have listened to the episode, click this link to claim your credit. Credit is available to NASPGHAN members (if you are not a member, you should probably sign up). And thank you to the NASPGHAN Professional Education Committee for their review!As always, the discussion, views, and recommendations in this podcast are the sole responsibility of the hosts and guests and are subject to change over time with advances in the field.Check out our merch website!Follow us on Bluesky, Twitter, Facebook and Instagram for all the latest news and upcoming episodes.Click here to support the show.

Forgiveness isn't just a church thing. It's not just a faith thing. It's a science thing. In this episode, Ryan Leak unpacks the astounding research from both Eastern and Western medicine on how unforgiveness, bitterness, and resentment impact your physical, emotional, and mental health. From impaired liver function in Chinese medicine to reduced risk of heart disease in Western studies, the evidence is clear: your body keeps the score of what your soul is carrying.Here are a few of the studies mentioned:World Journal of Gastroenterology on liver function and chronic anger: linkJohns Hopkins Medicine on the health benefits of forgiveness: linkJournal of Behavioral Medicine study on forgiveness and mental health: linkMayo Clinic on forgiveness and stress relief: linkBut science can only take you so far. If you're wondering how to actually forgive, Ryan points to the model and the power found in Jesus Christ. If you'd like to take the next steps in your faith journey or receive prayer, text “Jesus” to 469-809-1201, and Ryan's team would love to connect with you.And if you want to dive even deeper into this topic, check out Ryan's full message on forgiveness here: Watch on YouTube

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Charles Kahi, MD Computer-aided detection systems (CADe) are transforming adenoma detection and enhancing colonoscopy quality. Dr. Peter Buch sits down with Dr. Charles Kahi to unpack the latest American Gastroenterological Association (AGA) guideline, evidence from randomized controlled trials, and the practical implications of integrating AI tools into clinical practice. Dr. Kahi is a Professor of Medicine at Indiana University School of Medicine, and he helped develop the AGA Living Clinical Practice Guideline on Computer-Aided Detection-Assisted Colonoscopy, which was published in Gastroenterology in 2025.

In this episode of our GI Mini-Series, we touch upon Acute Pancreatitis covering its diagnosis, causes, classification, and management. The podcast also highlights risk factors for severe disease, fluid resuscitation strategies, pain control, early oral feeding, and the role of antibiotics. Tune in for an evidence-based, guideline-driven deep dive into the topic, filled with practical bedside insights you can put into practice right away.Author and Host: Dr. Ruchir Paladiya, Chief Medical Resident, UConnGuest Speaker: Dr. Neil Khoury, UConn GI Fellowship Alumnus (2022–25) and Assistant Professor of Medicine, University of South Florida (Tampa General Hospital)Editor: Dr. Ruchir Paladiya, Chief Medical Resident, UConnMusic: LoFi Girl by Snoozy Beats | Free Music Archive | License: CC BY 

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Alexa Weingarden, MD PhD Probiotic use in gastroenterology remains a complex and evolving topic, shaped by variable evidence and growing patient demand. Dr. Peter Buch sits down with Dr. Alexa Weingarden to review current data, discuss distinctions between probiotic-related therapies, and explore the clinical utility of microbiome testing. Dr. Weingarden is an Assistant Professor of Gastroenterology, Hepatology, and Nutrition at the University of Minnesota Medical School.

Featuring: David T. Rubin, MD, University of Chicago MedicineThe GI Research Foundation was able to produce this podcast with sponsorships from Metro Infusion Center.David T. Rubin, MD, Joseph B. Kirsner Professor of Medicine and Chief of Gastroenterology, Hepatology and Nutrition at the University of Chicago Medicine, explores the top ten challenges faced by people with Crohn's disease and ulcerative colitis. He shares how health care providers and researchers are working to overcome these obstacles and improve patients' lives.To access other episodes of Visceral: Listen to Your Gut and learn more about the GI Research Foundation's support of clinical and laboratory research to treat, prevent, and cure digestive diseases, please visit https://www.giresearchfoundation.org/.Available on Apple Podcasts, Spotify, and everywhere else you listen.

Featuring: David T. Rubin, MD, University of Chicago MedicineThe GI Research Foundation was able to produce this podcast with sponsorships from Metro Infusion Center.David T. Rubin, MD, Joseph B. Kirsner Professor of Medicine and Chief of Gastroenterology, Hepatology and Nutrition at the University of Chicago Medicine, explores the top ten challenges faced by people with Crohn's disease and ulcerative colitis. He shares how health care providers and researchers are working to overcome these obstacles and improve patients' lives.To access other episodes of Visceral: Listen to Your Gut and learn more about the GI Research Foundation's support of clinical and laboratory research to treat, prevent, and cure digestive diseases, please visit https://www.giresearchfoundation.org/.Available on Apple Podcasts, Spotify, and everywhere else you listen.

So you've placed the biliary drain—are your patients getting the follow up that they need? In this episode, Dr. Ahsun Riaz from Northwestern University joins host, Dr. Christopher Beck, for a deep dive into biliary strictures—how to manage them effectively and navigate the potential complications of this challenging chronic condition.---This podcast is supported by:Medtronic Emprinthttps://www.medtronic.com/emprint---SYNPOSISDr. Riaz takes us inside his journey of building a specialized hepatobiliary service at Northwestern, highlighting innovative practices like endoscopic techniques and radiofrequency ablation. He unpacks the nuances of distinguishing benign from malignant strictures, shares technical pearls for patient management, and emphasizes the power of collaboration with Gastroenterology to improve long-term patient outcomes. He outlines key technical considerations, including the use of the Hudson loop and strategic equipment selection to address intra-procedural challenges. He further emphasizes the importance of comprehensive patient care—ensuring appropriate follow-up, minimizing drain duration, and prioritizing quality of life as essential components of optimal management.---TIMESTAMPS00:00 - Introduction01:28 - Biliary Drain Management04:18 - Approach to Biliary Strictures19:20 - Endoscopic Evaluation and Techniques27:53 - Practical Tips and Experiences with Endoscopy30:39 - Post-Procedure Follow-Up and Patient Outcomes31:16 - Learning from the Hudson Roof Technique32:48 - Innovations in Benign Stricture Management36:48 - Endobiliary Ablation: Equipment and Procedure40:23 - The Double Dragon Technique Explained46:02 - Considerations for Malignant Biliary Stenting52:37 - Future Innovations and Collaborative Care

Send us a textComedian Ian Goldstein takes us through his journey with Crohn's disease, beginning with his diagnosis at 16 when he was just trying to navigate the already challenging world of high school, SATs, and planning for college. With candid humor, he recounts the moment he realized something was seriously wrong – not just from frequent bathroom trips, but when a coworker pointed out his dramatic weight loss.What follows is a rollercoaster of medical experiences that many in the IBD community will recognize – from the shock of needing a colonoscopy as a teenager to the trial and error of finding effective medications. Ian vividly describes his first major bowel obstruction during his senior year of college, complete with what he calls the "modern-day torture device" known as an NG tube. Despite his best efforts to manage his condition through diet alone, he eventually required surgery in 2022 to remove seven strictures from his small intestine.The conversation takes a fascinating turn when Ian shares how he's transformed his medical journey into comedy shows. From "The Autoimmune Saloon" to a celebration party for meeting his healthcare deductible (complete with custom cupcakes and hats), he's found ways to create community while addressing serious issues like medical debt. These creative outlets not only helped him process his experiences but connected him with others who could offer crucial advice about doctors and treatments.Perhaps most valuable are Ian's insights about navigating the healthcare system with a chronic illness. He speaks honestly about the frustration of insurance denials, the anxiety of unexpected medical bills, and the challenges of having an invisible disability. His experiences highlight the importance of self-advocacy, finding the right medical team, and building a supportive community.Ready to laugh, cry, and feel a little less alone in your IBD journey? Listen as Ian shares his practical wisdom: record your doctor appointments to remember important information, and seek out community connections that might literally change your life. Whether you're newly diagnosed or a veteran of chronic illness, this conversation reminds us all that finding humor in dark places might be our most powerful medicine.Links: Ian's websiteNew York Times article about Ian's party to celebrate meeting his healthcare deductibleThe Squeaky Wheel- satire publication that focuses on the experiences of people living with disabilities. Tina's episode with usDr. David Schwartzberg's episode with usNicole's episode with us- Ian mentioned Nicole and how supportive she's been to him but we sadly had to cut that part out for length. But- get to know Nicole!! Let's get social!!Follow us on Instagram!Follow us on Facebook!Follow us on Twitter!

Living with Inflammatory Bowel Disease (IBD) means encountering life-changing challenges, but it doesn't have to define your future. Jannine Purcell, CNP, Gastroenterology, discusses how IBD affects young adults in their 20s and 30s, often disrupting major life milestones. Jannine explains the difference between Crohn's disease and ulcerative colitis and why team-based care is essential. She shares inspiring success stories of patients who've achieved deep remission and provides insight into why close follow-up and patient education are crucial for helping young people reclaim their quality of life. Hosted on Acast. See acast.com/privacy for more information.

C'est une question qui revient souvent, car la banane a la réputation ambiguë de constiper. Mais que disent les données scientifiques ?D'abord, il faut savoir que toutes les bananes ne se valent pas ! Tout dépend de son degré de maturité. Une banane encore verte contient beaucoup d'amidon résistant, une forme d'amidon que l'intestin grêle digère mal. Résultat : il arrive presque intact dans le côlon, où il nourrit le microbiote. Cet amidon a un effet plutôt rassasiant, mais peut aussi ralentir un peu le transit. C'est probablement de là que vient la croyance que les bananes « bloquent ».En revanche, quand elle mûrit, l'amidon de la banane se transforme en sucres simples et la teneur en fibres solubles, comme la pectine, augmente. Ces fibres solubles retiennent l'eau dans l'intestin et ramollissent les selles, ce qui favorise au contraire un meilleur transit. Autrement dit : une banane mûre a plutôt un effet régulateur qu'un effet constipant.Qu'en dit la science ? Une étude publiée en 2014 dans le World Journal of Gastroenterology a montré que l'amidon résistant de la banane verte ralentissait effectivement le transit intestinal chez certains sujets sensibles. Mais d'autres travaux, comme une revue parue en 2017 dans Nutrients, soulignent le rôle bénéfique des fibres de la banane mûre dans la prévention de la constipation, notamment chez les enfants.Chez l'enfant justement, une étude menée en 2012 au Sri Lanka sur plus de 350 écoliers (Journal of Nutrition and Metabolism) a révélé que la consommation de banane mûre réduisait significativement les plaintes de constipation. Les auteurs insistent cependant : l'effet dépend du degré de maturité du fruit et de l'alimentation globale de l'enfant.En pratique, tout est donc une question de nuance :Banane verte → plus d'amidon résistant, peut ralentir le transit.Banane mûre → plus de sucres et de fibres solubles, aide à ramollir les selles.Dernier point : la banane contient aussi du potassium et du magnésium, qui participent à la contraction musculaire, y compris celle des muscles intestinaux. Un apport régulier contribue ainsi à un transit équilibré.Verdict : faux, la banane ne constipe pas… sauf si elle est encore verte. Mûre, elle agit même plutôt comme un régulateur naturel du transit. Hébergé par Acast. Visitez acast.com/privacy pour plus d'informations.

In this episode of Bowel Sounds, hosts Dr. Peter Lu and Dr. Jason Silverman talk to Dr. Amber Hildreth, pediatric gastroenterologist and transplant hepatologist at Rady Children's Hospital and Assistant Professor at the University of California San Diego. She is also a clinician scientist at the Rady Children's Institute for Genomic Medicine. We discuss how genetic testing is transforming the way we care for children with rare GI and liver diseases.Learning objectivesRecognize key differences between various types of genetic testing.Discuss several applications of genetic testing in care for children with GI disorders.Understand the role of the genetic counselor in integrating genetic testing into GI practice.Support the showThis episode may be eligible for CME credit! Once you have listened to the episode, click this link to claim your credit. Credit is available to NASPGHAN members (if you are not a member, you should probably sign up). And thank you to the NASPGHAN Professional Education Committee for their review!As always, the discussion, views, and recommendations in this podcast are the sole responsibility of the hosts and guests and are subject to change over time with advances in the field.Check out our merch website!Follow us on Bluesky, Twitter, Facebook and Instagram for all the latest news and upcoming episodes.Click here to support the show.

Send us a message with this link, we would love to hear from you. Standard message rates may apply.Colon cancer screening saves lives by catching cancer early and even preventing it, yet only 69% of eligible adults are up to date with their screenings. We explore who needs screening, what tests are available, and how to choose the right one for you.• Most adults should start colon cancer screening at age 45, even if healthy• Family history may mean you need to start screening earlier• Stool-based tests like FIT and Cologuard are convenient home options• Colonoscopy remains the gold standard, allowing doctors to remove polyps• One in 23 men and one in 25 women will develop colorectal cancer• The best screening test is the one you'll actually completePlease get screened! Check with your doctor about which test is right for you based on your risk factors and preferences.References1. Screening for Colorectal Cancer in Asymptomatic Average-Risk Adults: A Guidance Statement From the American College of Physicians (Version 2). Qaseem A, Harrod CS, Crandall CJ, et al. Annals of Internal Medicine. 2023;176(8):1092-1100. doi:10.7326/M23-0779.2. AGA Clinical Practice Update on Risk Stratification for Colorectal Cancer Screening and Post-Polypectomy Surveillance: Expert Review. Issaka RB, Chan AT, Gupta S. Gastroenterology. 2023;165(5):1280-1291. doi:10.1053/j.gastro.2023.06.033.3. Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement. Davidson KW, Barry MJ, Mangione CM, et al. JAMA. 2021;325(19):1965-1977. doi:10.1001/jama.2021.6238.4. Colorectal Cancer Screening and Prevention. Sur DKC, Brown PC. American Family Physician. 2025;112(3):278-283.5. Increasing Incidence of Early-Onset Colorectal Cancer. Sinicrope FA. The New England Journal of Medicine. 2022;386(16):1547-1558. doi:10.1056/NEJMra2200869.6. From Guideline to Practice: New Shared Decision-Making Tools for Colorectal Cancer Screening From the American Cancer Society. Volk RJ, Leal VB, Jacobs LE, et al. CA: A Cancer Journal for Clinicians. 2018;68(4):246-249. doi:10.3322/caac.21459.7. Screening for Colorectal Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. Lin JS, Perdue LA, Henrikson NB, Bean SI, Blasi PR. JAMA. 2021;325(19):1978-1998. doi:10.1001/jama.2021.4417.8. Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement. Bibbins-Domingo K, Grossman DC, Curry SJ, et al. JAMA. 2016;315(23):2564-2575. doi:10.1001/jama.2016.5989.9. How Would You Screen This Patient for Colorectal Cancer? : Grand Rounds Discussion From Beth Israel Deaconess Medical Center. Burns RB, Mangione CM, Weinberg DS, Kanjee Z. Annals of Internal Medicine. 2022;175(10):1452-1461. doi:10.7326/M22-1961.Support the showSubscribe to Our Newsletter! Production and Content: Edward Delesky, MD & Nicole Aruffo, RNArtwork: Olivia Pawlowski

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Yinghong Wang, MD, PhD, MS Immune checkpoint inhibitor (ICI) colitis comes with unique diagnostic and treatment challenges, which means that recognizing and managing it effectively is key to the best outcomes. Joining Dr. Peter Buch to share her insights on caring for patients with this complex condition is Dr. Yinghong Wang. Dr. Wang is a Professor in the Department of Gastroenterology, Hepatology, and Nutrition at MD Anderson Cancer Center in Houston, Texas, as well as Director of the Oncology-GI Toxicity Program, Director of Fecal Microbiota Transplantation, Deputy Division Head of Research in the Division of Internal Medicine, and Chair of the MD Anderson Cancer Center Immunotherapy Toxicity Working Group.

Featuring: David T. Rubin, MD, University of Chicago Medicine The GI Research Foundation was able to produce this podcast with sponsorships from Metro Infusion Center. David T. Rubin, MD, Joseph B. Kirsner Professor of Medicine and Chief of Gastroenterology, Hepatology and Nutrition at the University of Chicago Medicine, explores challenges 6-10 of the top ten faced by people with Crohn's disease and ulcerative colitis. He explains how providers and researchers are working to overcome these challenges and improve care for patients. To access other episodes of Visceral: Listen to Your Gut and learn more about the GI Research Foundation's support of clinical and laboratory research to treat, prevent, and cure digestive diseases, please visit https://www.giresearchfoundation.org/. Available on Apple Podcasts, Spotify, and everywhere else you listen.

What does preventive care really mean for people living with inflammatory bowel disease (IBD)? In this episode, we break down the latest ACG Clinical Guideline Update: Preventive Care in IBD with two of its lead authors, Dr. Francis Farraye (Mayo Clinic, Jacksonville, FL) and Dr. Freddy Caldera (University of Wisconsin School of Medicine and Public Health). Together, we explore: Why preventive care is critical in IBD management Key vaccination recommendations for IBD patients How to prioritize cancer and bone health screening The role of mental health and lifestyle in long-term outcomes Produced in collaboration with the American College of Gastroenterology's Patient Care Committee, this episode offers clear, evidence-based insights for both patients and providers.  

Send us a textImagine visiting your gastroenterologist and feeling comfortable enough to discuss every aspect of how IBD affects your life—including your sexual health and practices. For many patients, particularly those in the LGBTQI+ community, this remains an elusive dream rather than reality.Dr. Victor Chedid, gastroenterologist and director of Mayo Clinic's Pride Clinic, joins Bowel Moments to tackle this crucial gap in IBD care. With disarming honesty and clinical expertise, he reveals why addressing sexuality isn't just about inclusivity—it's about providing complete medical care. When 95% of providers believe discussing sexual health is important but only 27% actually do it, patients suffer in silence with questions that directly impact their quality of life.The conversation dives deep into practical approaches for both patients and providers. Dr. Chedid shares his framework for discussing sexual practices with patients, from the straightforward question "What do you do for sex?" to navigating complex conversations around surgical interventions like J-pouch formation. For transgender patients, he unpacks recent research on gender-affirming hormones and IBD, emphasizing that life-saving gender-affirming care should never be withheld due to IBD concerns.Perhaps most compelling is Dr. Chedid's perspective on cultural humility and intersectionality. Each patient's experience is shaped by multiple overlapping identities—their sexuality, gender, race, nationality, and more. Rather than making assumptions, he advocates for providers to "leave their biases at the door" and approach each person's unique situation with curiosity and respect."People living with IBD are the experts of their own bodies," Dr. Chedid reminds us in his powerful closing thoughts. "When they say something feels off, it's not a guess—it's lived experience." This principle forms the foundation of truly inclusive care—care that sees patients as whole people deserving of dignity, understanding, and comprehensive treatment.Ready to advocate for more inclusive IBD care? Share this episode with your healthcare team and join the conversation about creating safe spaces for everyone in our community.Links: AGA's Pride Month Provider Spotlight on Dr. ChedidDr. Chedid talking about forming the IBD Pride Clinic"Your Top 6 Questions Answered by Dr. Victor Chedid" -A Program Dedicated to IBD Patients from the LGBTQIA+ Community- Crohn's & Colitis Foundation- USALet's get social!!Follow us on Instagram!Follow us on Facebook!Follow us on Twitter!

In this enlightening episode of the Productivity Smarts Podcast, host Gerald J. Leonard sits down with Dr. Mohammad Farivar, a board-certified gastroenterologist and author of “Is It IBS or Your Diet?”. With more than 55 years of medical experience, Dr. Farivar brings deep insights into the connection between gut health, productivity, and overall well-being.   Many people struggle with Irritable Bowel Syndrome (IBS), a condition that can drastically impact daily life, work performance, and even mental clarity. Dr. Farivar reveals how diet, stress, and gut health play pivotal roles in both IBS symptoms and productivity and why traditional treatments often miss the mark.   Through real-life patient stories and science-backed strategies, you'll discover how small dietary shifts, the right testing, and an informed approach to gut health can make a world of difference.   Whether you or someone you know is battling digestive health issues, this conversation will equip you with practical steps to regain control and unlock your full potential.   What We Discuss [00:00] Introduction to Dr. Mohammad Farivar [05:47] Impact of IBS on patients' lives [09:12] Motivation to write the book [12:19] Proper approach to IBS diagnosis [15:12] IBS and productivity loss [17:21] Stress and its effects on IBS [22:54] Critique of probiotic industry [27:16] FODMAP diet explained [30:44] Complementary and alternative medicine for IBS [32:44] Hydrogen breath test for IBS [37:19] Where to find the book and final advice   Notable Quotes [05:03] “We are all born with a mission. Even as a child, I knew I wanted to be a doctor.” – Dr. Farivar   [06:39] “In my practice, I was able to find the cause of IBS in more than 90% of cases — most of the time, it was diet-related.” – Dr. Farivar   [15:12] “IBS is the second most common cause of lost productivity after colds and infections.” – Dr. Farivar   [22:59] “Forget probiotics. A spoonful of yogurt gives you more than any pill.” – Dr. Farivar   Resources   Dr. Mohammad Farivar Website - IsItIBSOrYourDiet.com LinkedIn: Mohammad Farivar Book: Is It IBS or Your Diet?   Productivity Smarts Podcast Website - productivitysmartspodcast.com   Gerald J. Leonard Website - geraldjleonard.com Turnberry Premiere website - turnberrypremiere.com Scheduler - vcita.com/v/geraldjleonard Kiva is a loan, not a donation, allowing you to cycle your money and create a personal impact worldwide. https://www.kiva.org/lender/topmindshelpingtopminds

Listen as pulmonologist Peter Dicpinigaitis discusses his approach to the diagnosis and management of patients with refractory chronic cough in the context of a clinically relevant case and provides insights regarding emerging therapies.PresenterPeter Dicpinigaitis, MDProfessor of MedicineAlbert Einstein College of MedicineDivision of Critical Care MedicineMontefiore Medical CenterDirector, Montefiore Cough CenterBronx, New YorkLink to full program:https://bit.ly/4kweynG

Send us a textThis discussion on ways to improve MASH patient management comes from the early July roundtable on "Major Issues of the First Six Months of 2025." As a reminder, that roundtable included the three co-hosts (Louise, Jörn Schattenberg and Roger Green) Louise drives this conversation based on two related issues she sees emerging: (i) increasing opportunities for motivated patients to manage their own health and (ii) managing the total patient in an environment where people may be taking incretin agonists as if they are consumer drugs. With increased access to scanning, providers can monitor patients (and patients can self-monitor) more closely. However, some of the issues a provider might find are tricky: patients who undertake what Louise describes as "the sneaky areas patients think are normal, but are probably contributing to disease" due to miseducation or no education on healthy eating and lifestyle, or patients purchasing and using incretin agonists through consumer channels, but possibly at subtherapeutic doses. Vigilance and probing are key here, but health systems will need to train more people on the types of probing that uncover underlying issues and behaviors that patients mistakenly believe to be healthy. The discussion also extends to the role of NITs in diagnosis and patient management, and how providers need to shift the paradigm away from describing a patient by fibrosis stage and instead focus on the amount of fat in the liver and its overall suppleness.

In this episode, hosts Drs. Peter Lu and Jason Silverman talk to Dr. Justine Turner about a non-biopsy approach to diagnosis for celiac disease in children. Dr. Turner is a Professor of Pediatrics and Divisional Director for the Division of Gastroenterology and Nutrition at the University of Alberta and also the medical lead for the Multidisciplinary Pediatric Celiac Disease Clinic at Stollery Children's Hospital in Edmonton. Learning Objectives:Review current clinical guidelines for the diagnosis of celiac disease in childrenUnderstand the potential pros and cons of a non-biopsy approach to diagnosis for celiac diseaseRecognize the potential impacts of serologic diagnosis for celiac disease on patients, their families and healthcare systemsLinks (to be added!!):Guideline for the diagnosis and treatment of celiac disease in children: recommendations of the North American Society for Pediatric Gastroenterology, Hepatology and NutritionNASPGHAN Clinical Report on the Diagnosis and Treatment of Gluten-related DisordersEuropean Society Paediatric Gastroenterology, Hepatology and Nutrition Guidelines for Diagnosing Coeliac Disease 2020Positive Predictive Value of Tissue Transglutaminase IgA for Celiac DiseaseSupport the showThis episode may be eligible for CME credit! Once you have listened to the episode, click this link to claim your credit. Credit is available to NASPGHAN members (if you are not a member, you should probably sign up). And thank you to the NASPGHAN Professional Education Committee for their review!As always, the discussion, views, and recommendations in this podcast are the sole responsibility of the hosts and guests and are subject to change over time with advances in the field.Check out our merch website!Follow us on Bluesky, Twitter, Facebook and Instagram for all the latest news and upcoming episodes.Click here to support the show.

Contributor: Alec Coston, MD Educational Pearls: Hepatic encephalopathy (HE) is defined as a disruption in brain function that results from impaired liver function or portosystemic shunting. Manifests as various neurologic and psychiatric symptoms such as confusion, inattention, and cognitive dysfunction Although ammonia levels have historically been recognized as important criteria for HE, the diagnosis is ultimately made clinically. An elevated ammonia level lacks sensitivity and specificity for HE Trends in ammonia levels do not correlate with disease improvement or resolution A 2020 study published in the American Journal of Gastroenterology evaluated 551 patients diagnosed with hepatic encephalopathy and treated with standard therapy Only 60% of patients had an elevated ammonia level, demonstrating the limitations of ammonia levels However, a normal ammonia level in a patient with concern for HE should raise suspicion for other pathology. In patients with cirrhosis presenting with neuropsychiatric symptoms, consider HE as the diagnosis after excluding other potential causes of altered mental status (i.e., Seizure, infection, intracranial hemorrhage) The primary treatment is lactulose Works by acidifying the gastrointestinal tract. Ammonia (NH₃) is converted into ammonium (NH₄⁺), which is poorly absorbed and subsequently eliminated from the body Also exerts a laxative effect, further enhancing elimination References: Haj M, Rockey DC. Ammonia Levels Do Not Guide Clinical Management of Patients With Hepatic Encephalopathy Caused by Cirrhosis. Am J Gastroenterol. 2020 May;115(5):723-728. doi: 10.14309/ajg.0000000000000343. PMID: 31658104. Lee F, Frederick RT. Hepatic Encephalopathy-A Guide to Laboratory Testing. Clin Liver Dis. 2024 May;28(2):225-236. doi: 10.1016/j.cld.2024.01.003. Epub 2024 Jan 30. PMID: 38548435. Vilstrup, Hendrik1; Amodio, Piero2; Bajaj, Jasmohan3,4; Cordoba, Juan1,5; Ferenci, Peter6; Mullen, Kevin D.7; Weissenborn, Karin8; Wong, Philip9. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study Of Liver Diseases and the European Association for the Study of the Liver. Hepatology 60(2):p 715-735, August 2014. | DOI: 10.1002/hep.27210 Weissenborn K. Hepatic Encephalopathy: Definition, Clinical Grading and Diagnostic Principles. Drugs. 2019 Feb;79(Suppl 1):5-9. doi: 10.1007/s40265-018-1018-z. PMID: 30706420; PMCID: PMC6416238. Summarized by Ashley Lyons, OMS3 | Edited by Ashley Lyons & Jorge Chalit, OMS4 Get your tickets to Tox Talks Event, Sept 11, 2025: https://emergencymedicalminute.org/events-2/ Donate: https://emergencymedicalminute.org/donate/  

Send us a textKey Opinion Leaders Manal Abdelmalek, Naim Alkhouri, Scott Isaacs and Zobair Younossi join Roger Green to discuss the FDA's approval of semaglutide for patients with non-cirrhotic MASH. This conversation centers on the roles that new technologies and an expanded APP population will play in MASLD and MASH management in the US, and concludes by exploring how care might look different 12 months from now, and then in subsequent years. As panelists identify some of the changes they foresee if we are to manage the tsunami of undiagnosed MASLD patients, many comments touch on themes discussed earlier in this episode. A couple are unique. Zobair and Scott discuss the increased role that artificial intelligence and big data analytics will play in identifying high-risk patients and improving clinical pathways. Additionally, Zobair notes that we must remember that the vast majority of MASLD patients will never develop MASH. Manal foresees a more sophisticated approach to selecting pharmacotherapies as prescribers have a broader set of options, each with its own benefits and drawbacks. Scott anticipates a "paradigm shift" in which endocrinologists view MASH similarly to how they view retinopathy, neuropathy and retinopathy. Naim suggests that one year will not look tremendously different from today, but that five years from now will be an entirely different picture, which he describes in some detail. 

Send us a textKey Opinion Leaders Manal Abdelmalek, Naim Alkhouri, Scott Isaacs and Zobair Younossi join Roger Green to discuss  FDA's approval of semaglutide for patients with non-cirrhotic MASH. This conversation focuses on benefits for patients and ways that having two drugs with different modes of action will change pharmacotherapy choices.This conversation starts with the group describing the sense of "enthusiasm" and "fulfillment" hepatology drug developers feel to see two drugs approved in the US and many other major changes to come (more drug approvals, FDA acceptance of a path to approval that is not based on liver biopsy). One interesting takeaway is that while the approval of semaglutide will likely change the number of patients treated with MASH pharmacotherapy, the greater impact of this approval will be on public awareness of MASH and the accompanying demand for treatment. In terms of actual drug use, the first major change will come among patients living with obesity but not Type 2 diabetes. Most of these patients previously saw their semaglutide prescriptions rejected for payment by health insurers. However, many of these patients will be living with MASH, and they are likely to see their prescriptions approved. Instead, the largest impact may involve increased education and awareness. Scott pointed out that endocrinologists, who frequently prescribe incretin agonists, will have reason to learn how to diagnose and manage MASH in patients they already treat. Zobair noted that an array of companies, starting with pharmaceutical manufacturers and scanning companies, will dramatically increase investments in prescriber and patient education. Another important benefit may come in terms of coverage. Scott points out that most patients living with obesity but not diabetes are unlikely to have their semaglutide prescriptions covered by commercial insurers. Those living with non-cirrhotic MASH are likely to have semaglutide covered. A separate but related point: Naim reports that ~30% of the MASH patients he sees are taking an incretin agonist at the time of initial visit.

In this special crossover podcast episode, Tuesday Night IBS hosts Jeffrey Roberts, MSEd, BSc, Erica Dermer and Kate Scarlata, MPH, RDN, are joined live by William Chey, MD, and Amanda Lynett, MS, RDN, at FOOD the Main Course Conference in Ann Arbor, MI. •    Intro :02 •    About Scarlata :30 •    About Chey 1:07 •    About Lynett 1:49 •    Chey, what are your goals for this year's FOOD the Main Course Conference? 2:58 •    How do you feel that mechanisms of diet are affecting microbiomes? 5:37 •    Amanda, what have you learned over the years as you have put together this conference, and how do you think this experience has shaped a more well-rounded program for clinicians?  8:23 •    What are you personally going to take away from the conference this year? 11:17 •    A discussion on peer-to-peer interactions, the spirit of collaborative care, and what each provider is bringing to the table. 12:22 •    Kate, tell us about why you come back to this conference every year. 17:32 •    What challenges did you overcome to move the needle forward in diet and GI conditions? 19:14 •    Chey, can you talk about the correlation between stress and diet when it comes to IBS? 24:21 •    How are we dealing with the ramifications of GLP-1s? 29:33 •    As providers, what is your first instinct when patients tell you they started GLP-1s? 32:28 •    How is the community going to help listeners weed through Internet noise to find accurate information? 35:01 •    Group discussion on the rise of severe constipation. 41:31 •    Who decides to send patients for colectomy consultations? 43:33 •    Is there anything else you want to share or highlight from the conference? 47:25 •    Thank you all 48:58 •    Thanks for listening 49:42 Erica Dermer is an IBS and Celiac Disease patient who hosts the Celiac and the Beast blog and You Had Me at Eat podcast series. Amanda Lynett MS, RDN, is a registered dietitian with her masters. Amanda is with the Division of Gastroenterology at Michigan Medical in Ann Arbor. Jeffrey Roberts, MSEd, BSc, is a patient advocate and creator of the first website for IBS sufferers. He is the co-founder of Tuesday Night IBS. Kate Scarlata, MPH, RDN, is a US-based dietitian with over 30 years of experience. Kate's expertise is in gastrointestinal disorders and food intolerance.  We'd love to hear from you! Send your comments/questions to guttalkpodcast@healio.com. Follow us on X @HealioGastro @sameerkberry @umfoodoc. For more Tuesday Night IBS, be sure check out TuesdayNightIBS.com and to follow and subscribe to their podcast. Disclosures: Chey and Roberts report no relevant financial disclosures. Scarlata reports stock options with Epicured LLC and FODY Food Company, financial support from Dr. Schar, Mahana Therapeutics, Nestle Health Science, Olipop, Pendulum, QOL Medical.

Send us a textFor two decades, Rachel Gebhardt has navigated the complex terrain of Crohn's disease with a refreshing perspective shaped by her father's experience with the same condition. Where her father let illness define him, Rachel chose a different path—one filled with humor, openness, and resilience—despite her case being more medically severe.Rachel's journey encompasses four bowel surgeries and fourteen hospital admissions since 2020 alone, including a colostomy she affectionately named "Whoopie." With disarming candor, she shares the moment her surgeon showed her a photo of a woman in an American flag bikini with a matching ostomy bag cover as encouragement—a moment that eventually inspired her own celebratory beachside photo years later. Through skin infections, bowel obstructions, and dietary restrictions, Rachel maintains her commitment to living fully and modeling positive coping for her children.The military healthcare system presented unique challenges, but also connected Rachel with Dr. Anish Patel at Brook Army Medical Center, who became not just her gastroenterologist but her advocate and ally. Their relationship exemplifies the profound difference compassionate, specialized care makes for patients with complex conditions. Rachel details her experience with hyperbaric treatments, medication complications, and the surprising remission she experienced only during pregnancy and breastfeeding—highlighting the understudied connection between hormones and IBD.What resonates most deeply is Rachel's transformation from initially viewing her ostomy as "the end of the world" to embracing it as a source of freedom. Now training for a half marathon and hiking mountains previously inaccessible when bathroom urgency controlled her life, she's become an outspoken advocate for ostomy awareness. Her message is clear and powerful: life with an ostomy can be not just manageable, but genuinely good—a perspective desperately needed by those facing similar paths. For anyone navigating IBD or supporting someone who is, Rachel's story offers both practical wisdom and heartening hope.Links: United Ostomy AssociationOur episode with Dr. Anish PatelPregnancy and Crohn's - video from Brigham & Women's IBD CenterPregnancy & Breastfeeding info- Crohn's Colitis UKLet's get social!!Follow us on Instagram!Follow us on Facebook!Follow us on Twitter!

Diverticulosis and diverticulitis sound alike but are very different conditions—and knowing the difference is key to protecting your digestive health. In this episode, host Jacqueline Gaulin welcomes Dr. Lisa Strate, Professor and Chief of Gastroenterology and Hepatology at the University of Wisconsin, and one of the nation's leading experts in diverticular disease. Together, they clear up common questions and misconceptions about diverticulosis and diverticulitis, including: What causes these conditions and who is most at risk The symptoms and warning signs patients should watch for Whether it's possible to have one without the other How diet and lifestyle affect treatment and prevention This episode is produced in collaboration with the American College of Gastroenterology's Patient Care Committee.  

In today's episode, we spoke with Masatoshi Kudo, MD, about the evolving treatment landscape in hepatocellular carcinoma (HCC) and how recent comparative analyses are helping refine the use of first-line immunotherapy-based regimens. Dr Kudo is a professor and chairman in the Department of Gastroenterology and Hepatology at Kindai University Faculty of Medicine in Osaka, Japan.

Featuring: David T. Rubin, MD, University of Chicago Medicine The GI Research Foundation was able to produce this podcast with sponsorships from Metro Infusion Center. David T. Rubin, MD, Joseph B. Kirsner Professor of Medicine and Chief of Gastroenterology, Hepatology and Nutrition at the University of Chicago Medicine, explores challenges 1–5 of the top ten faced by people with Crohn's disease and ulcerative colitis. He shares how health care providers and researchers are working to overcome these obstacles and improve patients' lives. To access other episodes of Visceral: Listen to Your Gut and learn more about the GI Research Foundation's support of clinical and laboratory research to treat, prevent, and cure digestive diseases, please visit https://www.giresearchfoundation.org/. Available on Apple Podcasts, Spotify, and everywhere else you listen.

In our last episode of the Bowel Sounds Summer School series (at least for this year), hosts Dr. Jason Silverman and Dr. Jennifer Lee have gathered highlights from past episodes on endoscopy to create an episode filled with clinical and teaching pearls.  Former expert guests Dr. Jenifer Lightdale, Dr. Catharine Walsh, and Dr. Looi Ee explain the elements of quality endoscopy, how to teach endoscopy, perform difficult colonoscopies, and even how to keep endoscopists healthy throughout their career.Be sure to also check out the great hands-on, colonoscopy skills and train the trainer workshops held during the NASPGHAN Annual Meeting each year!Our Bowel Sounds Summer School series includes four episodes on big topics in our field, artisanally crafted for the ears of learners of all stages from the young student to the seasoned attending.Learning Objectives:Review the technical and non-technical components of quality endoscopic procedures.Understand communication strategies that help preceptors effectively teach endoscopy skills to trainees.Review the relevant elements of ergonomics and systemic factors that can help prevent endoscopy-related injuries. Featured Episodes:Jenifer Lightdale - PEnQuINs and Making Pediatric Endoscopy Safer (November 2020)Catharine Walsh - Education in Endoscopy (November 2022)Looi Ee - The Challenging Colonoscopy: Down Under Edition (August 2023)Links:NASPGHAN/ESPGHAN Society Papers on Endoscopy (2022)Other Summer School Episodes:Bowel Sounds Summer School - Constipation in ChildrenBowel Sounds Summer School - Eosinophilic EsophagitisBowel SoundsSupport the showThis episode may be eligible for CME credit! Once you have listened to the episode, click this link to claim your credit. Credit is available to NASPGHAN members (if you are not a member, you should probably sign up). And thank you to the NASPGHAN Professional Education Committee for their review!As always, the discussion, views, and recommendations in this podcast are the sole responsibility of the hosts and guests and are subject to change over time with advances in the field.Check out our merch website!Follow us on Bluesky, Twitter, Facebook and Instagram for all the latest news and upcoming episodes.Click here to support the show.

In the corner of the ICU, on multiple pressors, distended, oliguric, and intubated you'll find the necrotizing pancreatitis patient. Sounds intimidating, but with the persistence, patience, and the proper care these patients can make it! In this episode from the HPB team at Behind the Knife listen in as we discuss the Step-Up approach, when to surgically intervene, various approaches to pancreatic Necrosectomy, and additional aspects of the multidisciplinary care required for the successful treatment of necrotizing pancreatitis.  Hosts Anish J. Jain MD (@anishjayjain) is a current PGY3 General Surgery Resident at Stanford University and a former T32 Research Fellow at the University of Texas MD Anderson Cancer Center. Jon M. Harrison is a 2nd year HPB Surgery Fellow at Stanford University. He will be joining as faculty at the Massachusetts General Hospital in Boston, MA at the conclusion of his fellowship in July 2024.    Learning Objectives ·      Develop an understanding of the severity of necrotizing pancreatitis and the proper indications to surgical intervene on this often-tenuous patients.  ·      Develop an understanding of the Step-Up approach and key aspects (reimaging, clinical status, physiologic status, etc.) that determine when to “step-up” treatment for patients with necrotizing pancreatitis. ·      Develop an understanding of long term sequalae and complications associated with necrotizing pancreatitis and operative management ·      Develop an understanding of multidisciplinary care and long-term follow-up necessary for adequate treatment of patients suffering from necrotizing pancreatitis. Suggested Reading Maurer LR, Fagenholz PJ. Contemporary Surgical Management of Pancreatic Necrosis. JAMA Surg. 2023;158(1):81–88. doi:10.1001/jamasurg.2022.5695 https://pubmed.ncbi.nlm.nih.gov/36383374/ Harrison JM, Day H, Arnow K, Ngongoni RF, Joseph A, Aldridge T, Wheeler KJ, DeLong JC, Bergquist JR, Worth PJ, Dua MM, Friedland S, Park W, Eldika S, Hwang JH, Visser BC. What's Behind it all: A Retrospective Cohort Study of Retrogastric Pancreatic Necrosis Management. Ann Surg. 2024 Sep 3. doi: 10.1097/SLA.0000000000006521. https://pubmed.ncbi.nlm.nih.gov/39225420/ Harrison JM, Visser BC. Not Dead Yet: Managing the Abdominal Catastrophe in Necrotizing Pancreatitis. Pancreas. 2025 May 20. doi: 10.1097/MPA.0000000000002512. https://pubmed.ncbi.nlm.nih.gov/40388698/ Harrison JM, Li AY, Sceats LA, Bergquist JR, Dua MM, Visser BC. Two-Port Minimally Invasive Nephrolaparoscopic Retroperitoneal Debridement for Pancreatic Necrosis. J Am Coll Surg. 2024 Dec 1;239(6):e7-e12. doi: 10.1097/XCS.0000000000001152. https://pubmed.ncbi.nlm.nih.gov/39051721/ van Santvoort HC, Besselink MG, Bakker OJ, Hofker HS, Boermeester MA, Dejong CH, van Goor H, Schaapherder AF, van Eijck CH, Bollen TL, van Ramshorst B, Nieuwenhuijs VB, Timmer R, Laméris JS, Kruyt PM, Manusama ER, van der Harst E, van der Schelling GP, Karsten T, Hesselink EJ, van Laarhoven CJ, Rosman C, Bosscha K, de Wit RJ, Houdijk AP, van Leeuwen MS, Buskens E, Gooszen HG; Dutch Pancreatitis Study Group. A step-up approach or open necrosectomy for necrotizing pancreatitis. N Engl J Med. 2010 Apr 22;362(16):1491-502. doi: 10.1056/NEJMoa0908821. https://pubmed.ncbi.nlm.nih.gov/20410514/ Bang JY, Arnoletti JP, Holt BA, Sutton B, Hasan MK, Navaneethan U, Feranec N, Wilcox CM, Tharian B, Hawes RH, Varadarajulu S. An Endoscopic Transluminal Approach, Compared With Minimally Invasive Surgery, Reduces Complications and Costs for Patients With Necrotizing Pancreatitis. Gastroenterology. 2019 Mar;156(4):1027-1040.e3. doi: 10.1053/j.gastro.2018.11.031. https://pubmed.ncbi.nlm.nih.gov/30452918/ Zyromski NJ, Nakeeb A, House MG, Jester AL. Transgastric Pancreatic Necrosectomy: How I Do It. J Gastrointest Surg. 2016 Feb;20(2):445-9. doi: 10.1007/s11605-015-3058-y. https://pubmed.ncbi.nlm.nih.gov/26691148/ Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.   If you liked this episode, check out our recent episodes here: https://app.behindtheknife.org/listen